Ovid Therapeutics, Inc. (OVID) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1241177,
    "name": "Ovid Therapeutics, Inc.",
    "stock_name": "Ovid Therapeutics, Inc.",
    "full_name": "Ovid Therapeutics, Inc.",
    "name_url": "stocks-analysis/ovid-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.62",
    "chg": 0.06,
    "chgp": "3.85%",
    "dir": 1,
    "prev_price": "1.56",
    "mcapval": "88.18",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US6904691010",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "625.3 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ovid-therapeutics-inc-1241177-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Ovid Therapeutics Hits New 52-Week High at $2.01, Marking Significant Milestone",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ovid-therapeutics-hits-new-52-week-high-at-201-marking-significant-milestone-3595632",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/OvidTherapeutic_priceRelatedfactors_3595632.png",
        "date": "2025-10-06 17:34:39",
        "description": "Ovid Therapeutics, Inc. has achieved a new 52-week high of USD 2.01, recovering from a previous low of USD 0.24. Despite this milestone, the company has faced a challenging year with a significant performance decline. Ovid's market capitalization is USD 88 million, and it remains loss-making."
      },
      {
        "title": "Ovid Therapeutics Hits New 52-Week High of $1.81, Marking Key Milestone",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ovid-therapeutics-hits-new-52-week-high-of-181-marking-key-milestone-3579356",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/OvidTherapeutic_priceRelatedfactors_3579356.png",
        "date": "2025-09-29 14:22:46",
        "description": "Ovid Therapeutics, Inc. has achieved a new 52-week high of USD 1.81, recovering from a low of USD 0.24. Despite this milestone, the company has faced a challenging year with a 44.19% decline in performance. Currently, it has a market capitalization of USD 88 million and is operating at a loss."
      },
      {
        "title": "Is Ovid Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ovid-therapeutics-inc-technically-bullish-or-bearish-3546324",
        "imagepath": "",
        "date": "2025-09-20 19:29:46",
        "description": "As of 3 September 2025, the technical trend for Ovid Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by a bullish MACD on the weekly chart and a bullish daily moving average. The KST is also bullish on the weekly timeframe. However, the monthly MACD is only mildly bullish, and the Bollinger Bands indicate a bearish stance on the monthly level. The Dow Theory presents a mixed view with a mildly bearish weekly signal and a mildly bullish monthly signal.\n\nIn terms of performance, Ovid Therapeutics has shown a strong 30.79% return over the past month, significantly outperforming the S&P 500, which returned 2.33% in the same period. However, over longer periods, the stock has underperformed the benchmark, particularly over 3 years and 5 years, with returns of -41.35% and -81.76%, respectively, compared to the S&P 500's gains...."
      },
      {
        "title": "Is Ovid Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ovid-therapeutics-inc-overvalued-or-undervalued-3542914",
        "imagepath": "",
        "date": "2025-09-20 18:05:38",
        "description": "As of 13 August 2025, the valuation grade for Ovid Therapeutics, Inc. has moved from does not qualify to risky, indicating increased concerns about the company's financial health. Based on the available metrics, Ovid appears to be overvalued given its negative performance indicators, including a price-to-book value of 0.38 and an EV to EBITDA ratio of 0.34. The company also has a return on equity (ROE) of -33.92%, which further underscores its financial struggles.\n\nWhen compared to peers, Ovid's valuation ratios are less favorable; for instance, KalVista Pharmaceuticals, Inc. has a more negative EV to EBITDA of -3.6594, while Fulcrum Therapeutics, Inc. does not qualify for valuation metrics. Additionally, Ovid's stock has underperformed relative to the S&P 500 over the long term, with a 5-year return of -81.76% compared to the S&P's 96.61%. This performance reinforces the notion that Ovid is currently overv..."
      }
    ],
    "total": 9,
    "sid": "1241177",
    "stock_news_url": "https://www.marketsmojo.com/news/ovid-therapeutics-inc-1241177"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Ovid Therapeutics Hits New 52-Week High at $2.01, Marking Significant Milestone

2025-10-06 17:34:39

Ovid Therapeutics, Inc. has achieved a new 52-week high of USD 2.01, recovering from a previous low of USD 0.24. Despite this milestone, the company has faced a challenging year with a significant performance decline. Ovid's market capitalization is USD 88 million, and it remains loss-making.

Ovid Therapeutics Hits New 52-Week High of $1.81, Marking Key Milestone

2025-09-29 14:22:46

Ovid Therapeutics, Inc. has achieved a new 52-week high of USD 1.81, recovering from a low of USD 0.24. Despite this milestone, the company has faced a challenging year with a 44.19% decline in performance. Currently, it has a market capitalization of USD 88 million and is operating at a loss.

Is Ovid Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:29:46

As of 3 September 2025, the technical trend for Ovid Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by a bullish MACD on the weekly chart and a bullish daily moving average. The KST is also bullish on the weekly timeframe. However, the monthly MACD is only mildly bullish, and the Bollinger Bands indicate a bearish stance on the monthly level. The Dow Theory presents a mixed view with a mildly bearish weekly signal and a mildly bullish monthly signal. In terms of performance, Ovid Therapeutics has shown a strong 30.79% return over the past month, significantly outperforming the S&P 500, which returned 2.33% in the same period. However, over longer periods, the stock has underperformed the benchmark, particularly over 3 years and 5 years, with returns of -41.35% and -81.76%, respectively, compared to the S&P 500's gains....

Is Ovid Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:05:38

As of 13 August 2025, the valuation grade for Ovid Therapeutics, Inc. has moved from does not qualify to risky, indicating increased concerns about the company's financial health. Based on the available metrics, Ovid appears to be overvalued given its negative performance indicators, including a price-to-book value of 0.38 and an EV to EBITDA ratio of 0.34. The company also has a return on equity (ROE) of -33.92%, which further underscores its financial struggles. When compared to peers, Ovid's valuation ratios are less favorable; for instance, KalVista Pharmaceuticals, Inc. has a more negative EV to EBITDA of -3.6594, while Fulcrum Therapeutics, Inc. does not qualify for valuation metrics. Additionally, Ovid's stock has underperformed relative to the S&P 500 over the long term, with a 5-year return of -81.76% compared to the S&P's 96.61%. This performance reinforces the notion that Ovid is currently overv...

View All News